瑞舒伐他汀对PCI术后患者APN和hs-CRP的影响

目的 探讨瑞舒伐他汀对经皮冠状动脉介入术(percutaneous coronary intervention,PCI)后患者血清脂联素(adiponectin,APN)和超敏C反应蛋白(high sensitivity C-reactive protein,hs-CRP)的影响.方法 108例成功进行PCI治疗的患...

Effect of Rosuvastatin on Serum APN and Hs-CRP in Patients after Percutaneons Coronary Intervention

Objective To investigate the effect of rosuvastatin on serum adiponectin（APN） and high-sensitivity C-reactive protein（hs-CRP） on patients after percutaneous coronary intervention（PCI）.Methods One hundred and eight patients with successful PCI were randomly divided into control group（46 cases） accepting conventional therapy and rosuvastatin group（62 cases） with oral administration of 10mg rosuvastatin each night besides the conventional therapy.Serum APN levels and hs-CRP levels were observed before PCI,one day,1 month,3 months and 6 months after PCI.Comparison and correlation analysis was performed.Results There was no significant difference in serum APN and hs-CRP levels between the two groups before PCI and one day after PCI（P0.05）.Serum APN levels were significantly increased and hs-CRP levels were obviously decreased in two groups 1 month,3 months and 6 months after intervention compared with those 1 day after PCI.Serum APN concentration was significantly higher in rosuvastatin group than that in control group,and blood hs-CRP level was significantly lower than that in control group（P0.01）.The blood APN levels were negatively related with hs-CRP levels（r=-0.330,P0.05）.Conclusion Rosuvastatin can significantly improve serum APN levels and decrease hs-CRP levels in the patients with coronary stent implantation so as to prevent and delay restenosis after PCI.